Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target boosted by HC Wainwright from $180.00 to $190.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other research firms have also weighed in on AXSM. Citigroup increased their price objective on shares […]
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target hoisted by Citigroup from $125.00 to $127.00 in a research note issued to investors on Tuesday, Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed an […]
Truist Financial reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $150.00 price objective on the stock. A number of other research analysts have also recently weighed in on AXSM. Mizuho lowered their price objective on Axsome Therapeutics […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities researchers at HC Wainwright from $180.00 to $190.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 145.64% from […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among […]